Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIRE-6: Avelumab + FOLFIRI + Cetuximab in RAS Wild-type Colorectal Cancer
NCT05217069Phase 2Completed
- Sponsor
- Ludwig Maximilian University of Munich
- Start
- Sep 2019
- Primary completion
- Sep 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in colorectal cancer (CRC), sponsored by Ludwig Maximilian University of Munich. Primary endpoint: Progression-Free Survival at 8 months. Started Sep 2019; status: completed.
02
Drugs
avelumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05217069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05217069.